The industry's claimed 'surprised' over the government's approach to the implementation, notably the 'double dipping' on statutory price reductions, appears to confront the significant challenge that it was warned of the risk last year but dismissed any concern.
The industry was warned last year but dismissed the risk of 'double dipping' on April reductions
October 10, 2022 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Olympian joins call urging vigilance on meningococcal risk
July 15, 2025 - - Latest News -
HTA reform is fine, but why is the underpinning framework immutable?
July 15, 2025 - - Latest News -
Patient Voice Initiative announces the appointment of new president
July 15, 2025 - - Latest News -
Amplia Therapeutics announces additional confirmed partial response in ACCENT trial
July 14, 2025 - - Australian Biotech -
Imugene reports two additional complete responses in azer-cel CAR T Phase 1b trial
July 14, 2025 - - Australian Biotech -
Is Australia in a position to lecture any country about affordable access to medicines?
July 14, 2025 - - Latest News -
Biotintelect amongst groups funded to foster research commercialisation
July 13, 2025 - - Australian Biotech